RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies targeting inflammatory and immunologic diseases. The company leverages proprietary expertise in immunology to create novel molecules designed to modulate immune system responses central to these diseases. Its pipeline includes RPT904, a monoclonal antibody aimed at binding free human immunoglobulin E (IgE) to address allergic conditions such as food allergy and chronic spontaneous urticaria. Additionally, RAPT is advancing small molecule CCR4 antagonists, including zelnecirnon for inflammatory diseases and tivumecirnon for oncology indications, reflecting its dual focus on immune-mediated inflammatory and cancer therapies. Operating with a clinical-stage approach, RAPT Therapeutics plays a significant role in developing next-generation treatments that meet unmet medical needs in immunology and oncology.